Regression of tumors by IFN-α electroporation gene therapy and analysis of the responsible genes by cDNA array

被引:35
作者
Li, S
Xia, X
Zhang, X
Suen, J
机构
[1] Henry Ford Hlth Syst, Dept Otolaryngol Head & Neck Surg, Detroit, MI 48202 USA
[2] Univ Arkansas Med Sci, Dept Otolaryngol Head & Neck Surg, Little Rock, AR 72205 USA
关键词
gene therapy; electroporation; IFN-alpha; antiangiogenesis; cDNA array;
D O I
10.1038/sj.gt.3301645
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The key to success with nonviral gene therapy as a treatment for cancer is to discover effective therapeutic genes and gene delivery methods and to understand how tumors are eradicated. We discovered that electroporation of IFN-alpha DNA into tumors in the SCCVII tumor-bearing mice led to tumor eradication in 50% of the mice and a more than twofold increase in survival time when compared with controls (P = 0.0012). Analyses using cDNA array and Northern blot indicated that the genes responsible for the therapeutic effect of electro-IFN-alpha gene therapy included IRF-7, Granzyme A, Granzyme C, Gjb2, Krt14, Mig, IP-10 and MCP3. Because most of these genes have been known to either inhibit angiogenesis (Mig, IP-10), inhibit tumor growth (Gjb2, MCP3), kill tumor cells (Granzyme A and C), or induce expression of antitumor gene (IRF-7), they may become promising therapeutic gene candidates for a combination gene therapy approach to cancer treatment.
引用
收藏
页码:390 / 397
页数:8
相关论文
共 44 条
[1]   In vivo tumor suppression by adenovirus-mediated interferon α2b gene delivery [J].
Ahmed, CMI ;
Sugarman, BJ ;
Johnson, DE ;
Bookstein, RE ;
Saha, DP ;
Nagabhushan, TL ;
Wills, KN .
HUMAN GENE THERAPY, 1999, 10 (01) :77-84
[2]   Gene transfer into muscle by electroporation in vivo [J].
Aihara, H ;
Miyazaki, J .
NATURE BIOTECHNOLOGY, 1998, 16 (09) :867-870
[3]   HUMAN INTERFERON-INDUCIBLE PROTEIN-10 IS A POTENT INHIBITOR OF ANGIOGENESIS IN-VIVO [J].
ANGIOLILLO, AL ;
SGADARI, C ;
TAUB, DD ;
LIAO, F ;
FARBER, JM ;
MAHESHWARI, S ;
KLEINMAN, HK ;
REAMAN, GH ;
TOSATO, G .
JOURNAL OF EXPERIMENTAL MEDICINE, 1995, 182 (01) :155-162
[4]   Transfer of the murine interleukin-12 gene in vivo by a Semliki Forest virus vector induces B16 tumor regression through inhibition of tumor blood vessel formation monitored by Doppler ultrasonography [J].
Asselin-Paturel, C ;
Lassau, N ;
Guinebretière, JM ;
Zhang, J ;
Gay, F ;
Bex, F ;
Hallez, S ;
Leclere, J ;
Peronneau, P ;
Mami-Chouaib, F ;
Chouaib, S .
GENE THERAPY, 1999, 6 (04) :606-615
[5]   Nephritogenic T tells use granzyme C as a cytotoxic mediator [J].
Bailey, NC ;
Kelly, CJ .
EUROPEAN JOURNAL OF IMMUNOLOGY, 1997, 27 (09) :2302-2309
[6]   ANTI-TUMOR EFFECTS OF INTERFERON IN MICE INJECTED WITH INTERFERON-SENSITIVE AND INTERFERON-RESISTANT FRIEND-LEUKEMIA CELLS .2. ROLE OF HOST MECHANISMS [J].
BELARDELLI, F ;
GRESSER, I ;
MAURY, C ;
MAUNOURY, MT .
INTERNATIONAL JOURNAL OF CANCER, 1982, 30 (06) :821-825
[7]   HUMAN RENAL-CARCINOMA LINE TRANSFECTED WITH INTERLEUKIN-2 AND OR INTERFERON-ALPHA GENE(S) - IMPLICATIONS FOR LIVE CANCER VACCINES [J].
BELLDEGRUN, A ;
TSO, CL ;
SAKATA, T ;
DUCKETT, T ;
BRUNDA, MJ ;
BARSKY, SH ;
CHAI, J ;
KABOO, R ;
LAVEY, RS ;
MCBRIDE, WH ;
DEKERNION, JB .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1993, 85 (03) :207-216
[9]   Nonviral interferon α gene therapy inhibits growth of established tumors by eliciting a systemic immune response [J].
Coleman, M ;
Muller, S ;
Quezada, A ;
Mendiratta, SK ;
Wang, JJ ;
Thull, NM ;
Bishop, J ;
Matar, M ;
Mester, J ;
Pericle, F .
HUMAN GENE THERAPY, 1998, 9 (15) :2223-2230
[10]   Tumor cell responses to IFNγ affect tumorigenicity and response to IL-12 therapy and antiangiogenesis [J].
Coughlin, CM ;
Salhany, KE ;
Gee, MS ;
LaTemple, DC ;
Kotenko, S ;
Ma, XJ ;
Gri, G ;
Wysocka, M ;
Kim, JE ;
Liu, L ;
Liao, F ;
Farber, JM ;
Pestka, S ;
Trinchieri, G ;
Lee, WMF .
IMMUNITY, 1998, 9 (01) :25-34